2018 Sponsors



Ruby — ($6,000 to $9,999)


Opal — ($3,000 to $5,999)


Sapphire — (Up to $2,999)


Sponsored Presentations

Sponsored Presentations are commercially supported educational sessions held in conjunction with the 2018 SPS Annual Meeting.

Sponsored Presentations will be held on Sunday, Monday, Tuesday, and Wednesday (September 30–October 3). Applications are accepted on a first come, first served basis and must be fully complete at the time of submission. Presentation slots will be sold until they are sold out. August 1, 2018, is the deadline to have sessions printed in the SPS Final Program. Complete the application.

September 30, 2018

12:30–13:30

Battelle

Hoover

Closed-Loop Regulation of Side Effects for Nerve Stimulation Therapeutics

Nerve stimulation is an emerging therapeutic option for the treatment of multiple diseases. We will present our current work using vagus nerve stimulation (VNS) to modulate cardiopulmonary physiology. Our technology platform uses machine learning to autonomously recognize VNS side effects, and regulate stimulation to increase this bioelectronic medicine’s safety profile.


October 1, 2018

07:00–08:00

Eurofins Pharma Discovery Services

Coolidge

The Mast Cell Receptor MrgX2 and Drug-Induced Anaphylaxis

Activation of MrgX2, a GPCR expressed on mast cells, leads to degranulation and histamine release. MrgX2 binds promiscuously to basic peptides and small molecules, resulting in acute histamine-like adverse drug reactions, both in man and in mammalian species used in drug toxicology. MrgX2 activity, across a panel of mammalian species, can be integrated into drug development to influence choice of compound, species model, and dosing regimen.


07:00–08:00

Ncardia

Hoover

Optogenetics and hiPSC-Derived Cells—Leap into the Future of Drug Screening

The cardiomyocyte and multiwell microelectrode array (MEA) assay offers an ideal approach to evaluate proarrhythmic indicators in vitro, and the addition of optogenetics provides unparalleled control of the assay. Learn how the combination of Axion BioSystems’ leading MEA technology and Ncardia’s new light-gated ion channel transfection technology provides an attractive assay for investigation of frequency-dependent responses of hiPSC-derived cardiomyocytes.

We are delighted to announce Ksenia Blinova, PhD (FDA) at the session presenting an update on the CiPA “Multisite study of stem cell-derived cardiomyocytes assays for proarrhythmic risk assessment."


12:30–13:30

ACEA Biosciences

Harding

Using Electrical Field Stimulation for Maturation of hiPSC Cardiomyocytes, Assessment of Inotropic Compounds and Cardiac Safety Assessment

One of the biggest gaps to full utilization of hiPSC-CM is their inherent maturation status. We will discuss the launch of a new high-throughput instrument that uses electrical conditioning to achieve fully functional mature cardiomyocytes that can be used to assess excitation-contraction coupling and other orthogonal assays. Dr. Xiaoyu Zhang (ACEA Bio) and Dr. Haoyu Zeng (Merck) will discuss how the system can provide incisive multi-parametric and predictive information for safety assessment, drug discovery, and cardiac disease modeling.


12:30–13:30

Axion Biosystems

Hoover

Beyond the CiPA Myocyte Assay: Tomorrow’s Tools Today

Trends in cardiac safety testing, as exemplified by CiPA and JiCSA, emphasize a move to integrated cellular models. The cardiomyocyte and multiwell microelectrode array (CM-MEA) assay offers an ideal approach to evaluate proarrhythmic indicators in vitro. Join Axion BioSystems to discuss advances in highly-multiplexed CM-MEA assays, fully exploiting the latent power of human cardiomyocyte models.


12:30–13:30

emka TECHNOLOGIES

Coolidge

Functional Capacity and Exercise: A Telemetry Light into the Dark End-Points of Cardiovascular Safety Pharmacology

Reduced functional capacity and impaired exercise tolerance are hallmarks of patient with inherited/acquired cardiomyopathies. However, quantitative tools for the preclinical assessment of both pathological and therapeutic changes indices reflective of these translational end-points remain limited. These experiments leverage the capacity of the easyTEL + telemetry systems in order to enhance both echocardiographic and functional (6minute walk test) assessments in conscious animals.


18:00–19:00

Alpha MED Scientific

Coolidge

High Sensitivity Microelectrode Array Assay for Neurotox Screening

The MED64 is a high-fidelity microelectrode array (MEA) platform that is engineered for sensitivity to detect a broad range of signals. In the presentation, researchers will demonstrate the power of high sensitivity MEAs for measuring epileptiform activity from stem cell-derived neurons and acute mouse hippocampal slices.


18:00–19:00

Nanion Technologies

Hoover

Good Cell and In Vitro Practices for Effectively Leveraging Cellular Functional Assays: An HTS Overview

In this session will we present, multiple high throughput patch clamping platforms for assessment of acute/chronic drug effects, a pioneering approach for simultaneous optogenetic stimulation and recording of electrophysiological and contractile parameters of iPS cardiomyocytes, and the application of these technologies for cardiac safety assessment in accordance with CiPA.


18:00–19:00

Novoheart

Wilson A

Next-Generation Drug Discovery with Novoheart’s MyHeart™ Platform, Including 3D Bioengineered Human Heart-In-A-Jar

Novoheart aims to revolutionize the inefficient process of drug development, offering the MyHeart™ Platform of bioartificial human pluripotent stem cell-derived heart tissue constructs, including the unique human ventricular Cardiac Organoid Chamber (hvCOC or human heart-in-a-jar), as versatile screening tools for predicting cardiotoxicity, as well as drug efficacy.


October 2, 2018

07:00–08:00

Clyde Biosciences

Hoover

iPSC-Derived Cardiomyocytes As an Inotropic Screen: Hits and Misses

This talk will discuss the differences in the process of excitation-contraction in iPSC-derived cardiomyocytes and adult heart cells. The consequences of the differences will be illustrated in terms of the response to known inotropic drugs, including a range of inotropic drugs with known pro-arrhythmic side effects.


12:30–13:30

Emka Technologies

Coolidge

Automated Blood Sampling and Dog Telemetry—3Rs Refinement and an Improvement to Preclinical Cardiovascular Safety Assessment

In this session Dr. Yevgeniya Koshman from AbbVie will walk us through AbbVie’s approach to drug safety with its use of EMKA’s telemetry and acute anesthetized systems. The case study will focus on the methods and advanced analysis that highlighted unique outcomes with the reduction of false positive detection.


12:3–13:30

FUJIFILM Cellular Dynamics

Hoover

Implementing Human iPSC-Derived Cells in Early Safety Assessment and Disease Modeling

Realize the predictive power of human iPSC-derived cells for in vitro toxicity testing. This session will highlight toxicology, drug screening, and disease models. Experts in the field will present case studies on optimization and assay development, using a consistent cell source. Demonstrating increased functionality and throughput valuable for identifying liabilities early in preclinical safety programs.


12:30–13:30

TSE Systems

Harding

A New Telemetry-Based System for Assessing Cardiovascular Function in Large Animals—Part III

The first pharmacological evaluation of a newly-developed total implant telemetry system in dogs and minipigs was done successfully. In this session you will find out how the system was evaluated in primates. In addition you will hear how the system can be used in a remote setting by using cloud data analysis. Real-time CV data from Primates in Mauritius will be presented.


October 3, 2018

12:00–14:00

Charles River

Taylor

The Role of the Functional Observational Battery (FOB) and Irwin Test Model in Safety Pharmacology

In collaboration with an international expert working group, the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) is conducting a survey to gather information on how FOB/Irwin test are carried out and how data is used to inform decision making during the development of pharmaceuticals. In this session, preliminary results from the survey will be discussed. We invite you to join the conversation and enjoy a complimentary lunch.


2018 Sponsorship Opportunities

With higher levels of sponsorship comes greater exposure. There are five levels of sponsorship available:

Sponsorship at this level requires a $15,000 contribution.
• Ability to host a Sponsored Presentation
• Company Name listed and logo displayed in Mobile App
• Company Name displayed in the General Session
• Company Name listed in the printed Program
• Company Name listed in pre-meeting promotional pieces
• Company Name on the Meeting website
• Verbal acknowledgment at the Plenary Lecture
• Verbal acknowledgment at the Awards Ceremony
• Acknowledgment on a meter board at the Annual Meeting
• Sponsor badge ribbon/s for your representatives

Sponsorship at this level requires a $10,000 contribution.
• Ability to host a Sponsored Presentation
• Company Name listed and logo displayed in Mobile App
• Company Name displayed in the General Sessions
• Company Name listed in the printed Program
• Company Name listed in pre-meeting promotional pieces
• Company Name on the Meeting website
• Verbal acknowledgment at the Plenary Lecture
• Verbal acknowledgment at the Awards Ceremony
• Acknowledgment on a meter board at the Annual Meeting
• Sponsor badge ribbon/s for your representatives

Sponsorship at this level requires a $6,000 contribution.
• Ability to host a Sponsored Presentation
• Company Name listed and logo displayed in Mobile App
• Company Name displayed in the General Sessions
• Company Name listed in the printed Program
• Company Name listed in pre-meeting promotional pieces
• Company Name on the Meeting website
• Verbal acknowledgment at the Plenary Lecture
• Verbal acknowledgment at the Awards Ceremony
• Acknowledgment on a meter board at the Annual Meeting
• Sponsor badge ribbon/s for your representatives

Sponsorship at this level requires a $3,000 contribution.
• Ability to host a Sponsored Presentation
• Company Name listed in the printed Program
• Company Name listed in pre-meeting promotional pieces
• Company Name on the Meeting website
• Verbal acknowledgment at the Plenary Lecture
• Verbal acknowledgment at the Awards Ceremony
• Acknowledgment on a meter board at the Annual Meeting
• Sponsor badge ribbon/s for your representatives

Sponsorship at this level is up to a $2,999 contribution.
• Ability to host a Sponsored Presentation (contribution of $2,500 or higher)
• Company Name listed in the printed Program
• Company Name listed in pre-meeting promotional pieces
• Company Name on the Meeting Website
• Acknowledgment on a meter board at the Annual Meeting
• Sponsor badge ribbon/s for your representativesSafety